Readable research linked to original sources

Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

2 articles

Newest first

Research Article 2019CC BY-NCFree full text · non-commercial reuse

Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.

Orrin Devinsky, Rima Nabbout, Ian Miller, Linda Laux, Marta Zolnowska, Stephen Wright +1 more

Objective Add-on cannabidiol (CBD) significantly reduced seizures associated with Dravet syndrome (DS) in a randomized, double-blind, placebo-controlled trial: GWPCARE1 Part B (NCT02091375). Patients who completed GWPCARE1 Part A (NCT02091206) or Part B, or a second placebo-controlled trial, GWPCARE2 (NCT02224703), were invited to enroll in a long-term open-label extension trial, GWPCARE5 (NCT02224573). We present…

Epilepsia Europe PMC

Open article record in new tab ↗

Research Article 2013CC BYFree full text

A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers.

Colin Stott, Linda White, Stephen Wright, Darren Wilbraham, Geoffrey Guy

Abstract This Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex (®), nabiximols) in combination with cytochrome P450 (CYP450) inducer (rifampicin) or inhibitors (ketoconazole or omeprazole). Thirty-six healthy male subjects were divided into three groups of 12, and then randomized…

SpringerPlus Europe PMC

Open article record in new tab ↗